Brought to you by 
Teva and AbCellera collaborate once again for monoclonal antibodies
13 Jun 2017
Executive Summary
In the second collaboration between AbCellera Biologics Inc. and Teva Pharmaceutical Industries Ltd., AbCellera agreed to once again apply its proprietary monoclonal antibody (mAb) screening platform to discover antibodies that modulate the function of an undisclosed membrane protein chosen by Teva.
Deal Industry
- Pharmaceuticals
- Research, Analytical Equipment & Supplies
-
Biotechnology
- Gene Therapy, Cell Therapy
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- Genomics-Proteomics
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Teva and AbCellera collaborate once again for monoclonal antibodies
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice